Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 3 - Studien 21 bis 30 von insgesamt 33
- Rekrutierung läuftOhrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie
- Rekrutierung läuftInternational, multicenter, non-interventional PASS study to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings
- Rekrutierung läuftPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Rekrutierung läuftA Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple MyelomaMolekulare Marker
- Rekrutierung läuftMYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)
- Rekrutierung läuftAnwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)NIS-Nr.:742
- Rekrutierung läuftA Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
- Rekrutierung läuftA non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -
- Rekrutierung läuftA Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma